Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

An unusual translocation, t(1;11)(q21;q23), in a case of chronic myeloid leukemia with a cryptic Philadelphia chromosome.

Gutiérrez LG, Noriega MF, Laudicina A, Quatrin M, Bengió RM, Larripa I.

Oncol Lett. 2017 May;13(5):3159-3162. doi: 10.3892/ol.2017.5845. Epub 2017 Mar 13.

2.

The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.

García-Tuñón I, Hernández-Sánchez M, Ordoñez JL, Alonso-Pérez V, Álamo-Quijada M, Benito R, Guerrero C, Hernández-Rivas JM, Sánchez-Martín M.

Oncotarget. 2017 Apr 18;8(16):26027-26040. doi: 10.18632/oncotarget.15215.

3.

Recurrent rearrangements of the Myb/SANT-like DNA-binding domain containing 3 gene (MSANTD3) in salivary gland acinic cell carcinoma.

Barasch N, Gong X, Kwei KA, Varma S, Biscocho J, Qu K, Xiao N, Lipsick JS, Pelham RJ, West RB, Pollack JR.

PLoS One. 2017 Feb 17;12(2):e0171265. doi: 10.1371/journal.pone.0171265. eCollection 2017.

4.

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T.

Blood. 2016 Apr 28;127(17):2131-43. doi: 10.1182/blood-2015-11-681171. Epub 2016 Feb 10.

5.

Coexistence of p190 BCR/ABL Transcript and CALR 52-bp Deletion in Chronic Myeloid Leukemia Blast Crisis: A Case Report.

Seghatoleslami M, Ketabchi N, Ordo A, Asl JM, Golchin N, Saki N.

Mediterr J Hematol Infect Dis. 2016 Jan 1;8(1):e2016002. doi: 10.4084/MJHID.2016.002. eCollection 2016.

6.

The Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic Malignancies.

Shingleton JR, Hemann MT.

PLoS One. 2015 Nov 20;10(11):e0143275. doi: 10.1371/journal.pone.0143275. eCollection 2015.

7.

Nanoparticle Formulations of siRNA: The Next Generation of Targeted Therapy for Lymphomas and Leukemias?

Wang AZ.

EBioMedicine. 2014 Nov 20;1(2-3):101-2. doi: 10.1016/j.ebiom.2014.11.013. eCollection 2014 Dec. No abstract available.

8.

Causes of genome instability: the effect of low dose chemical exposures in modern society.

Langie SA, Koppen G, Desaulniers D, Al-Mulla F, Al-Temaimi R, Amedei A, Azqueta A, Bisson WH, Brown DG, Brunborg G, Charles AK, Chen T, Colacci A, Darroudi F, Forte S, Gonzalez L, Hamid RA, Knudsen LE, Leyns L, Lopez de Cerain Salsamendi A, Memeo L, Mondello C, Mothersill C, Olsen AK, Pavanello S, Raju J, Rojas E, Roy R, Ryan EP, Ostrosky-Wegman P, Salem HK, Scovassi AI, Singh N, Vaccari M, Van Schooten FJ, Valverde M, Woodrick J, Zhang L, van Larebeke N, Kirsch-Volders M, Collins AR.

Carcinogenesis. 2015 Jun;36 Suppl 1:S61-88. doi: 10.1093/carcin/bgv031. Review.

9.

Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.

Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Brümmendorf TH, Matczak E, Bardy-Bouxin N, Shapiro M, Turnbull K, Leip E, Cortes JE.

Am J Hematol. 2015 Sep;90(9):755-68. doi: 10.1002/ajh.24034. Epub 2015 Jun 1.

10.

Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.

de Oliveira GA, Rangel LP, Costa DC, Silva JL.

Front Oncol. 2015 Apr 29;5:97. doi: 10.3389/fonc.2015.00097. eCollection 2015. Review.

11.

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.

Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, Sheng Z, Druker BJ, Li S, Green MR.

Sci Transl Med. 2014 Sep 3;6(252):252ra121. doi: 10.1126/scitranslmed.3009073.

12.

Prodrug applications for targeted cancer therapy.

Giang I, Boland EL, Poon GM.

AAPS J. 2014 Sep;16(5):899-913. doi: 10.1208/s12248-014-9638-z. Epub 2014 Jul 9. Review.

13.

BxPC3 pancreatic cancer cells express a truncated Smad4 protein upon PI3K and mTOR inhibition.

Legendre O, Sookdeo A, Foster DA.

Oncol Lett. 2014 Apr;7(4):1165-1168. Epub 2014 Jan 28.

14.

Optimisation of tetrahydroisoquinoline-based chimeric microtubule disruptors.

Dohle W, Leese MP, Jourdan FL, Chapman CJ, Hamel E, Ferrandis E, Potter BV.

ChemMedChem. 2014 Aug;9(8):1783-93. doi: 10.1002/cmdc.201402025. Epub 2014 May 12.

15.

DNA damage response and DNA repair - dog as a model?

Grosse N, van Loon B, Rohrer Bley C.

BMC Cancer. 2014 Mar 19;14:203. doi: 10.1186/1471-2407-14-203.

16.

A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL.

Rix U, Colinge J, Blatt K, Gridling M, Remsing Rix LL, Parapatics K, Cerny-Reiterer S, Burkard TR, Jäger U, Melo JV, Bennett KL, Valent P, Superti-Furga G.

PLoS One. 2013 Oct 10;8(10):e77155. doi: 10.1371/journal.pone.0077155. eCollection 2013.

17.

Chromosomal structural variations during progression of a prostate epithelial cell line to a malignant metastatic state inactivate the NF2, NIPSNAP1, UGT2B17, and LPIN2 genes.

Malhotra A, Shibata Y, Hall IM, Dutta A.

Cancer Biol Ther. 2013 Sep;14(9):840-52. doi: 10.4161/cbt.25329. Epub 2013 Jul 26.

18.

Genetic variation and its role in malignancy.

Talseth-Palmer BA, Scott RJ.

Int J Biomed Sci. 2011 Sep;7(3):158-71.

19.

Cancer-linked targets modulated by curcumin.

Hasima N, Aggarwal BB.

Int J Biochem Mol Biol. 2012;3(4):328-51. Epub 2012 Dec 24.

20.

Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells.

Belle L, Bruck F, Foguenne J, Gothot A, Beguin Y, Baron F, Briquet A.

PLoS One. 2012;7(12):e52564. doi: 10.1371/journal.pone.0052564. Epub 2012 Dec 20.

Supplemental Content

Support Center